Mitsui Chemicals, Inc. manufactures and sells petrochemicals and industrial inorganic chemical products. It operates through the following segments: Mobility, Healthcare, Food and Packaging, Base Material, and Others. The Mobility segment covers the new product development support business (solution business) for elastomers, functional compounds, functional polymers, polypropylene compounds, automobiles and other industrial products. The Healthcare segment includes vision care material, non-woven fabric, dental material, and personal care material. The Food and Packaging segment handles the coating and functional materials, functional films and sheets, and agricultural chemicals. The Base Material segment covers the ethylene, propylene, polyethylene, polypropylene, catalysts, phenols, high-purity terephthalic acid, PET resins, polyurethane materials, and industrial chemicals. The Others segment comprises of other related businesses. The company was founded on July 1, 1955 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Pharmaceutical concern

Plasmia Biotech SL, part of 1nKemia IUCT Group SA, is a Spanish company located in Barcelona. The firm provides pharmaceutical development and research services. 1nKemia IUCT Group SA acquired Plasmia Biotech SL on May 30, 2017 for $0.22 million.

Manufactures, marketes and imports, exports pharmaceutical drugs

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. It also provides consulting and biotechnology services. The company's products include abiraterone acetate, anastrozole, apixaban, apremilast, atazanavir sulfate, azacitidine, benazepril hydrochloride, bortezomib, capecitabine, celecoxib, cladribine, dantrolene sodium, decitabine, desmopressin acetate, docetaxel anhydrous, docetaxel trihydrate, entecavir, enzalutamide, exemestane, flumazenil, fulvestrant, galantamine, gefitinib, gemcitabine hydrochloride, ondansetron hydrochloride, and paclitaxel. ScinoPharm Taiwan was founded on November 11, 1997 and is headquartered in Tainan, Taiwan.

Xinxiang Pharmaceutical Co., Ltd., established on 1996-12-25, Business scope includes licensed projects:Food additive production;pharmaceutical production;Drug import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Chemical product production(No licensed chemical products);Manufacturing of basic chemical raw materials(Manufacture of licensed chemicals free of hazardous chemicals);Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Chemical product sales(No licensed chemical products);Specialty Chemicals Sales(Free of Hazardous Chemicals);Import and export;Technology Import and Export;Non-residential real estate leases;Machinery and Equipment Leasing(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Tuoxin Pharmaceutical Group Co., Ltd. engages in the research, development, production and sale of chemical synthetic biological fermented nucleoside APIs and pharmaceutical intermediates. It offers series of nucleoside (nucleotide) products including pyrimidine series, purine series, nucleotide series and nucleoside series, including citicoline sodium, ribavirin, inosine, cytosine, 5-fluorocytosine, cytidine and other raw materials and pharmaceutical intermediates. The company's products mainly covering antiviral, anti-tumor and nervous system medicine n terms of production management system. Xinxiang Tuoxin Pharmaceutical was founded on August 2, 2001 and is headquartered in Xinxiang, China.

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia, due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs, to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

Nanjing Pinsheng Medical Laboratory Co., Ltd., established on 2018-01-22, Business scope includes licensed projects:Class III medical device business;Production of Class II Medical Devices;medical service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Socioeconomic Advisory Services;Organize cultural and artistic exchange activities;Conference and Exhibition Services;Natural science research and experimental development;Sales of Class I Medical Devices;Sales of Class II Medical Devices;electronics sales;Daily necessities sales;Machinery sales;Manufacturing of computer software, hardware and peripheral equipment;Retailing of computer software, hardware and auxiliary equipment;Information system integration service;Production of Class I Medical Devices;Electrical Equipment Sales;Domestic trade agent;trade broker;marketing planning;sales agent;Machinery and Equipment Leasing;Computer and communication equipment rental;Medical equipment rental;Office equipment rental service(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Nanjing Pinsheng Medical Technology Co., Ltd., established on 2019-03-11, Business scope includes licensed projects:Import and export;Technology Import and Export;Production of Class II Medical Devices;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development;Health Consulting Services(Does not include medical services);Socioeconomic Advisory Services;Organize cultural and artistic exchange activities;Conference and Exhibition Services;Natural science research and experimental development;Sales of Class I Medical Devices;Sales of Class II Medical Devices;electronics sales;Daily necessities sales;Machinery sales;Manufacturing of computer software, hardware and peripheral equipment;Retailing of computer software, hardware and auxiliary equipment;Information system integration service;Production of Class I Medical Devices;Corporate Headquarters Management;business management;Electrical Equipment Sales;Domestic trade agent;trade broker;marketing planning;sales agent;market survey;Machinery and Equipment Leasing;Computer and communication equipment rental;Medical equipment rental;Office equipment rental service(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shanghai Ammonia Biotechnology Co., Ltd., established on 2017-10-24, Business scope includes licensed projects:Internet Information Service for Medical Devices;Inspection and testing service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Natural science research and experimental development;Class I Medical Device Leasing;Sales of Class I Medical Devices;Experimental analysis instrument sales;software development;internet data service;Big data service;data processing services;Data processing and storage support services;Health Consulting Services(Does not include medical services);Domestic trade agent;trade broker;market survey(Does not include foreign investigations);Import and export;Technology Import and Export;Import and export agency;Specialty Chemicals Sales(Free of Hazardous Chemicals).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shandong Boyuan Pharmaceutical Co., Ltd. is a Chinese company located in Jinan. The firm manufactures and wholesales pharmaceutical products. It was founded in 2005.

Chengdu Jingshi Biochemical Technology Co., Ltd., established on 2007-09-14, Business scope includes biotechnology and products(Does not contain drugs and blood products,food),Chemical Technology and Products(Free of drugs and dangerous chemicals)Research,to develop,Sales and technical consultation,Technical Services,technology transfer;pharmaceutical technology research,Development and Technical Consulting,Technical Services,Technology allows;Import and export,Technology Import and Export;(National laws of the above business scope,Except where prohibited by administrative regulations;law,Operate after obtaining a license restricted by administrative regulations).

Ningxia Huaji Biological Co., Ltd., established on 2019-08-09, Business scope includesD-ribose,L-arginine,L-Glutamine,calcium aspartate,Valine,Leucine,Isoleucine,Citrulline,Ornithine,Theanine,Production and sales of fucoidan oligosaccharides;Biotechnology,drug development,Technology Development and Transfer;XXTechnical Advisory Services;Business Management Consulting,Marketing Planning Consulting;Business Management Consulting;Enterprise Marketing Planning;Business Consulting;Planning of medical academic exchange activities;Chinese patent medicine,Chinese Herbal Medicine,Chemicals,Chemical API,antibiotic preparation,biochemical drug,Biological product,Psychotropic drugs(Class II),Anabolics,Peptide Hormone Wholesale,Production,Sales;nutritious food,drinks,Healthy food,Lycium barbarum enzyme,Fruit and vegetable enzymes and enzyme beverage products,Production of special dietary food,Sales,research and development,technical consulting,technology transfer;agricultural products,Souvenir,Preparation and storage of prepackaged food,Sales(Including online);food processing,Sales(according to<food business license>Licensed scope of operation);Pharmaceutical Intermediates(Does not contain narcotics,Country Restricted),Production and sales of adenine;Production and sales of flavors and fragrances****(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (doing business as Chia Tai-Tianqing Pharmaceutical Co Ltd) is a company headquartered in Lianyungang, China. The firm manufactures pharmaceutical products. It was founded in 1969. Kang Xin Yu is the current CEO of the firm.

Suzhou Puheng Technology Co., Ltd., established on 2021-08-21, Business scope includes licensed projects:Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Machinery sales;Sales of Class I Medical Devices;Chemical product sales(No licensed chemical products);Computer System Services;software development;Artificial intelligence basic software development;Artificial intelligence application software development;data processing services;Specialty Chemicals Sales(Free of Hazardous Chemicals);Instrument sales;translation service(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Nanjing Yadong Qitian Pharmaceutical Co., Ltd., established on 2003-08-04, Business scope includes pharmaceutical production(Operate according to the items listed in the drug production license);Research on new drugs and biological products,to develop,technology transfer;medical technology,Biotechnology research and development and technical services,technology transfer,technical consulting;Health food sales(A license or approval is required to operate);Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Biochem Pharma, Inc. provides bioinfomatics tools, biotechnology databases and consulting services to the genomics, proteomics and biopharmaceutical industries. They provide the cutting edge strategic intelligence needed to exploit information and to develop future business strategies.

Pharmasset Inc is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Their primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus, or HBV, hepatitis C virus, or HCV and human immunodeficiency virus, or HIV. Their research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication. They are currently focusing on three product candidates, two of which they are developing themselves and one of which they are developing with a strategic partner: • Clevudine, for the treatment of HBV, expected to enter Phase 3 registration clinical trials in the second calendar quarter of 2007; • R7128, a pro-drug of PSI-6130 for the treatment of HCV, in a Phase 1 clinical trial; and • Racivir, for the treatment of HIV, in a Phase 2 clinical trial.